Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings
Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 关于获得创新药HSK47388片新适应症《药物临床试验批准通知书》的公告 | 2025-09-03 | Chinese | |
| 关于创新药HSK47977片获得FDA药物临床试验批准的公告 | 2025-09-01 | Chinese | |
| 关于使用自有资金支付募投项目部分款项并以募集资金等额置换的公告 | 2025-08-22 | Chinese | |
| 2025年半年度募集资金存放与实际使用情况的专项报告 | 2025-08-22 | Chinese | |
| 中信证券股份有限公司关于海思科医药集团股份有限公司使用自有资金支付募投项目部分款项并以募集资金等额置换的核查意见 | 2025-08-22 | Chinese | |
| 半年度非经营性资金占用及其他关联资金往来情况汇总表 | 2025-08-22 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 36671805 | 关于获得创新药HSK47388片新适应症《药物临床试验批准通知书》的公告 | 2025-09-03 | Chinese | ||
| 36671793 | 关于创新药HSK47977片获得FDA药物临床试验批准的公告 | 2025-09-01 | Chinese | ||
| 36671784 | 关于使用自有资金支付募投项目部分款项并以募集资金等额置换的公告 | 2025-08-22 | Chinese | ||
| 36671774 | 2025年半年度募集资金存放与实际使用情况的专项报告 | 2025-08-22 | Chinese | ||
| 36671765 | 中信证券股份有限公司关于海思科医药集团股份有限公司使用自有资金支付募投项目部分款项并以募集资金等额置换的核查意见 | 2025-08-22 | Chinese | ||
| 36671758 | 半年度非经营性资金占用及其他关联资金往来情况汇总表 | 2025-08-22 | Chinese | ||
| 36671742 | 2025年半年度报告摘要 | 2025-08-22 | Chinese | ||
| 36671734 | 2025年半年度财务报告 | 2025-08-22 | Chinese | ||
| 36671716 | 半年报董事会决议公告 | 2025-08-22 | Chinese | ||
| 36671713 | 2025年半年度报告 | 2025-08-22 | Chinese | ||
| 36671709 | 关于获得创新药HSK39297片新适应症IND申请《受理通知书》的公告 | 2025-08-17 | Chinese | ||
| 36671701 | 北京市中伦律师事务所关于海思科医药集团股份有限公司2025年度向特定对象发行A股股票的补充法律意见书 | 2025-08-13 | Chinese | ||
| 36671657 | 2025年度向特定对象发行A股股票募集说明书（修订稿） | 2025-08-13 | Chinese | ||
| 36671549 | 中信证券股份有限公司关于海思科医药集团股份有限公司向特定对象发行A股股票之上市保荐书 | 2025-08-13 | Chinese | ||
| 36671546 | 信永中和会计师事务所关于海思科医药集团股份有限公司申请向特定对象发行股票的审核问询函之回复报告 | 2025-08-13 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Haisco Pharmaceutical Group Co.,Ltd via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/54674/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=54674 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=54674 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=54674 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 54674}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Haisco Pharmaceutical Group Co.,Ltd (id: 54674)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.